Antigen News and Research

RSS

New $1.4M grant supports innovative kidney cancer treatment strategy

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

10 Dec 2024

Breakthrough discovery in BK polyomavirus replication offers hope for kidney transplant protection

BK polyomavirus, or BKPyV, is a major cause of kidney transplant failure. There are no effective drugs to treat BKPyV.

6 Dec 2024

45 years of progress: Prevention and screening avert millions of cancer deaths

Research shows that cancer prevention and screening efforts prevented 5.94 million deaths across five major cancer types, highlighting their critical role.

6 Dec 2024

PAGER technology unlocks new potential for controlling cellular activity

A basic function of cells is that they act in response to their environments. It makes sense, then, that a goal of scientists is to control that process, making cells respond how they want to what they want.

5 Dec 2024

Study identifies key immune cells that could protect the brain after cardiac arrest

Despite improvements in CPR and rates of getting patients to the hospital, only about 10 percent of people ultimately survive after out-of-hospital cardiac arrest (OHCA), translating to about 300,000 deaths per year in the United States.

5 Dec 2024

Cancer cells block T-cell activation, but new therapies restore immune defenses

Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment. Restoring balance through PGE2 inhibition and IFN-I enhancement could renew immune defenses and improve immunotherapy outcomes.

4 Dec 2024

Ultrasound-controlled CRISPR offers precision in treating genetic disorders

Thanks to CRISPR, our medical specialists will soon have unprecedented control over how they treat and prevent some of our most challenging genetic disorders and diseases.

4 Dec 2024

Exploring the potential of MSCs in cancer therapy

A new review was published in Oncotarget's Volume 15 on November 22, 2024, entitled "Mesenchymal stem cells – the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists."

4 Dec 2024

Spatial transcriptomics uncovers new treatment paths for triple-negative breast cancer

Study uses spatial transcriptomics to map intratumoral heterogeneity and microenvironmental dynamics in triple-negative breast cancer (TNBC). The findings identify nine spatial archetypes and gene signatures linked to immunotherapy response and patient outcomes.

2 Dec 2024

IL-15 improves the effectiveness of GPC3 CAR T cells in targeting solid tumors

The study reveals IL-15's role in enhancing GPC3 CAR T cell therapy, improving tumor targeting and T cell survival in patients with solid cancers.

2 Dec 2024

New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia

FELIX study results reveal obe-cel's potential in relapsed B-cell ALL, achieving 77% remission with low severe toxicity, enhancing CAR T-cell therapy outcomes.

2 Dec 2024

Phase 1 study finds serine- and glycine-free diet boosts immune response in colorectal cancer

Findings indicate a serine/glycine-free diet can reduce colorectal cancer growth and enhance immune response, offering insights for immunotherapy strategies.

29 Nov 2024

Demographic and socioeconomic factors impact prostate cancer detection in Ireland

Recent findings from a study on prostate cancer in Ireland reveal diagnosis disparities, especially in urban areas and middle socioeconomic groups.

28 Nov 2024

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.

27 Nov 2024

Revolutionary strategy offers hope for type 1 diabetes treatment

Regenerative medicine holds the extraordinary promise that future patients in need of new cells, tissues or organs will no longer have to rely on donors. Organ shortages and cell type mismatches will become past problems, replaced by safe, on-demand options for anyone who needs a transplant.

25 Nov 2024

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Growth Factors Group, in collaboration with researchers of the Cancer Research Program of Hospital del Mar Research Institute (HMRI), Barcelona, have developed novel chimeric antigen receptor (CAR) T-cell therapy that can produce a potent antitumor response against p95HER2-expressing cells.

19 Nov 2024

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

A new phase 1 trial demonstrates the safety and effectiveness of personalized neoantigen DNA vaccines, showing promising immune responses and improved recurrence-free survival in high-risk triple-negative breast cancer patients.

17 Nov 2024

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Researchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR T-cells. This breakthrough enhances tumor targeting while reducing off-target effects, paving the way for advanced synthetic biology applications.

17 Nov 2024

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient.

15 Nov 2024

Customizable biological sensors activate cancer immunotherapy only in tumor environments

Most cancer treatments – from chemotherapies to engineered immune cells – have a host of side effects, in large part because they affect healthy cells in the body at the same time as targeting tumor cells.

15 Nov 2024

Antigen News and Research

New $1.4M grant supports innovative kidney cancer treatment strategy

Breakthrough discovery in BK polyomavirus replication offers hope for kidney transplant protection

45 years of progress: Prevention and screening avert millions of cancer deaths

PAGER technology unlocks new potential for controlling cellular activity

Study identifies key immune cells that could protect the brain after cardiac arrest

Cancer cells block T-cell activation, but new therapies restore immune defenses

Ultrasound-controlled CRISPR offers precision in treating genetic disorders

Exploring the potential of MSCs in cancer therapy

Spatial transcriptomics uncovers new treatment paths for triple-negative breast cancer

IL-15 improves the effectiveness of GPC3 CAR T cells in targeting solid tumors

New study explores obecabtagene autoleucel for adults with hard-to-treat leukemia

Phase 1 study finds serine- and glycine-free diet boosts immune response in colorectal cancer

Demographic and socioeconomic factors impact prostate cancer detection in Ireland

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Revolutionary strategy offers hope for type 1 diabetes treatment

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer

Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

Customizable biological sensors activate cancer immunotherapy only in tumor environments

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics